High-throughput SARS-CoV-2 Antigen Assay

High-throughput SARS-CoV-2 Antigen Assay

Lab-based antigen testing for rapid virus detection: Time to first result in as little as 26 minutes

Early detection is key to limiting infection and reducing community transmission. High-throughput, central lab-based SARS-CoV-2 antigen testing is a cost-effective and highly scalable complement to molecular RT-PCR diagnostic testing in the fight against COVID-19.

  • Increases testing capacity to support testing of large groups and organizations.
  • Detects positive cases quickly, allowing timely follow-up and implementation of protective measures.
  • Provides accurate results, including for patients who are asymptomatic or in the early stage of the disease.
  • Protects your laboratory staff by inactivating the virus with a pretreatment.

The SARS-CoV-2 Antigen Assays are now available on the Atellica® IM Analyzer and ADVIA Centaur® XPT/XPT Systems*.

Emerging Variants

Importance of Monitoring Emerging SARS-CoV-2 Variants to Ensure Antigen Assay Effectiveness White Paper

Importance of Monitoring Emerging SARS-CoV-2 Variants to Ensure Antigen Assay Effectiveness White Pape

Just as newly-approved vaccines begin to offer the prospect of a return to normalcy, the emergence of broadly-circulating SARS-CoV-2 variants has raised significant concerns about vaccine efficacy.1-3

This new whitepaper discusses the differences between mutants, variants, and strains, and how they might affect SARS-CoV-2 antigen testing. Learn about Variants of Concern (VOCs) and how enhanced surveillance supports earlier identification.

Because of their increased risk to public health, Siemens Healthineers is committed to the continuous monitoring of emerging variants and conducting evaluations to help ensure that our assays remain effective at detecting them. Our SARS-CoV-2 Antigen assay features antibodies that maximize variant detection, including the rapidly-spreading Omicron and Delta variants.

Large Scale Testing

As the pandemic persists, demand for testing continues to increase, placing great pressure on large organizations and communities to efficiently identify COVID-19 infection. Lab-based antigen testing can be easily integrated on currently available high-throughput instruments already being used for routine diagnostic testing at clinics, reference labs, and hospitals today or can be installed at a mass testing site.

Suspected COVID-19 Outbreaks Icon

Suspected COVID-19 outbreaks 

  • In remote settings, institutions, and semi-closed communities where PCR is not immediately available.
  • Positive results from multiple patients may suggest an outbreak and would allow for earlier implementation of infection control measures.
Domestic and International Traveler Testing Icon

Domestic and International Traveler Testing

  • Efficient and scalable passenger testing for airports, train stations, and cruise ships.
  • More effective identification of at-risk individuals to rapidly isolate positive cases (and initiate other contact tracing efforts) and prioritize sample collection for PCR confirmation as needed.
Large Organizations and Facilities Icon

Large Organizations and Facilities

  • Ongoing monitoring to help prevent widespread infection within institutions and workplaces such as schools, offices, dormitories, factories, correctional institutions, medical facilities, etc.
  • Areas of widespread community transmission where the positive predictive value and negative predictive value of an antigen result are sufficient to enable effective infection control.

Siemens Healthineers SARS CoV-2 Antigen Tests

  • Enable high-volume capacity for testing large organizations and crowded facilities
  • Produce accurate results with rapid turnaround time, at reduced costs
  • Provide automated result reporting

Now available on the Atellica® IM Analyzer and ADVIA Centaur® XP/XPT Systems*, with over 9,000 high-throughput analyzers worldwide4

Atellica IM 1300 Analyzer,  Atellica IM 1600 Analyzer

Atellica IM SARS-CoV-2 Antigen Assay

Time to first result: 26 minutes5
200 tests per hour6

ADVIA Centaur XPT Immunoassay System

ADVIA Centaur SARS-CoV-2 Antigen Assay

Time to first result: 28 minutes5
125 tests per hour6

Assay Details



Time to First Result

440 tests/hour7

26 minutes

240 tests/hour7

28 minutes

Comparative PCR Method (Ct<30)





95% Confidence Interval

Atellica IM Analyzer




93.74 - 98.46%

ADVIA Centaur XP/XPT Systems




93.58 - 98.42%

Comparative PCR Method (Ct<30)






95% Confidence Interval

Atellica IM Analyzer

n = 380




99.03% - 100%

ADVIA Centaur XP/XPT Systems

n = 375




98.52% - 99.99%

We are committed to supporting frontline and healthcare professionals and helping them to deliver high-value critical care to patients at each stage of COVID-19 disease management: diagnosis, prognosis, therapy, and follow-up. Learn more.